Management of type 2 diabetes with Saptavimshatika Guggulu and Haridra Churna – A multicenter clinical trial

Type 2 diabetes (T2DM) is a chronic metabolic disease characterized by insulin resistance and insufficient insulin production. In Ayurvedic medicine, diabetes is referred to as Madhumeha. This study investigates the efficacy of Saptavimshatika Guggulu (SG) and Haridra Churna (HC) in the treatment of T2DM.

Method

In this multicenter clinical trial, 146 patients diagnosed with T2DM were treated with SG (1 g, two tablets twice daily after meals) and HC (3 g, twice daily after meals with lukewarm water) over a period of 12 weeks. Patients were assessed using the Diabetes Symptoms Questionnaire (DSQ) and the SF-36 Health Survey score. Changes in HbA1c, fasting blood glucose (FBS) and postprandial blood glucose (PPBS) were also assessed.

Results

The results showed significant improvements in several parameters:

Fasting blood sugar (FBS): reduction from 167.44 mg/dL to 152.83 mg/dL

Postprandial blood glucose (PPBS): reduction from 261.74 mg/dL to 240.59 mg/dL

HbA1c: No significant changes

Diabetes Symptoms Questionnaire (DSQ): Decrease in score from 38.74 to 13.41

SF-36 Health Survey Score: Significant improvements in all eight domains, including physical functioning, emotional well-being and social functioning.

The Ayurvedic formulations Saptavimshatika Guggulu and Haridra Churna showed significant improvement in blood glucose levels and quality of life in T2DM patients. The formulations were found to be safe and well tolerated, with no significant side effects or complications. Further studies are needed to evaluate the long-term efficacy and impact on HbA1c.